They estimate that about 55% of patients would still be alive 4 years after receiving axi-cel, compared with 46% of those who initially received the standard treatment for relapsed disease. The study investigators presented their findings June 5 at the American Society of Clinical Oncology (ASCO) annual meeting. Now, new data from the ZUMA-7 clinical trial strongly suggests that axi-cel, as this CAR T-cell therapy is often called, can offer real hope for this latter group of patients. But for those who aren’t, the prospects of a cure have been uncertain at best, even with additional grueling chemotherapy and stem cell transplant. Most people diagnosed with diffuse large B-cell lymphoma, the most common form of aggressive NHL, will be cured by initial treatment with chemotherapy. That’s according to updated results from a large randomized phase 3 clinical trial of the CAR T-cell therapy axicabtagene ciloleucel (Yescarta). CAR T-cell therapy, a type of personalized immunotherapy, can help cure some people with aggressive non-Hodgkin lymphoma (NHL).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |